Selective NPY (Y5) antagonists

Details Selective NPY (Y5) antagonists Selective NPY (Y5) antagonists

2007-09-25

2007-09-25

Anderson, Rebecca (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

11040328

ABSTRACT:
This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

REFERENCES:
patent: 3128272 (1964-04-01), Wear et al.
patent: 4383113 (1983-05-01), Levitt et al.
patent: 5166214 (1992-11-01), Billheimer et al.
patent: 5232921 (1993-08-01), Biziere et al.
patent: 5238936 (1993-08-01), Regnier et al.
patent: 5536722 (1996-07-01), Coe et al.
patent: 5550138 (1996-08-01), Sohda et al.
patent: 6124331 (2000-09-01), Marzabadi et al.
patent: 6214853 (2001-04-01), Marzabadi et al.
patent: 6218408 (2001-04-01), Marzabadi et al.
patent: 6222040 (2001-04-01), Marzabadi et al.
patent: 6225330 (2001-05-01), Marzabadi et al.
patent: 6340683 (2002-01-01), Marzabadi et al.
patent: 6569856 (2003-05-01), Marzabadi et al.
patent: 19824175 (1999-12-01), None
patent: 0 283 390 (1988-09-01), None
patent: 0 432 040 (1991-02-01), None
patent: 0 448 078 (1991-09-01), None
patent: 0 775 487 (1997-05-01), None
patent: 57151653 (1982-09-01), None
patent: WO93/23381 (1993-11-01), None
patent: WO94/18212 (1994-08-01), None
patent: WO96/19457 (1996-06-01), None
patent: WO97/19682 (1997-06-01), None
patent: WO97/20823 (1997-06-01), None
patent: WO98/35944 (1998-08-01), None
patent: WO98/35957 (1998-08-01), None
patent: WO99/01128 (1999-01-01), None
patent: WO99/05138 (1999-02-01), None
patent: WO99/32466 (1999-07-01), None
patent: WO99/62892 (1999-12-01), None
patent: WO 00/64880 (2000-11-01), None
patent: WO 00/68197 (2000-11-01), None
patent: WO 01/23389 (2001-04-01), None
patent: WO 01/44201 (2001-06-01), None
patent: WO 01/64675 (2001-09-01), None
Turnbull et al., Selective Antagonism of the NPY Y5 receptor Does Not Have a Major Effect on Feeding in Rats, Diabetes: 51, pp. 2441-2449, (2002).
Criscione et al., J Clin Invest, 102(12), 2136-2145, (1998).
Bentancur, et al., TIPS vol. 18 (1997), 372-386.
Berlin, et al., Proc. Okla. Acad. Sci. 71 (1991): 29-33.
Brown, et al., Aust. J. Chem. 34 (1981): 2423-2429.
Khazi, et al., J. Heterocyclic Chem., 4 (1995): 243-248.
McNally J.J., et al., Bio. Med. Chem. Lett., 10 (2002): 212-216.
Ohkubo, M., et al., Chem. Pharm. Bull., 43(9) (1995): 1479-1504.
Peesapati, et al., OPPI Briefs, 25(5) (1993): 602-606.
Wettstein, J.G., et al., Pharmac. Ther. 65, 397-414.
Wieland, et al. Expert Opin. Investig. Drugs; 9(6)(2000): 1327-1346.
Xia, et al., Bioorg. Med. Chem. Lett. 6(7) (1996): 919-922.
Yamane, Kameji, Nippon Kagaku Zasshi 91(4) (1970): 395-399.
Yamane, et al., Nippon Kagaku Zasshi 90(6) (1969): 569-571.
Yamane, et al., Nippon Kagaku Zasshi 89(6) (1968): 612-614.
Turnbull, et al., Diabetes: 51 (2002), 2441-2449.
Erondu et al., “Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults,”Cell Metabolism4:275-282 (Oct. 2006).
Shionogi & Co., Ltd., “Shionogi announces positive results from a Phase IIa study of S-2367, a novel neuropeptide Y5 receptor antagonist for the treatment of Obesity,” (Jul. 10, 2006).

Affiliated with

Also associated with

Rating

Selective NPY (Y5) antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective NPY (Y5) antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective NPY (Y5) antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3724702